🇺🇸 FDA
Patent

US 11084809

N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

granted A61KA61K31/4439A61K31/445

Quick answer

US patent 11084809 (N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors) held by KalVista Pharmaceuticals Limited expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4439, A61K31/445, A61K31/496, A61P